Depressor Mechanism of Enalapril in Rats Made Hypertensive by Norepinephrine or Vasopressin

Abstract

We evaluated the antihypertensive mechanism of enalapril, a long-lasting inhibitor of angiotensin-converting enzyme, in rats made hypertensive by chronic infusion of norepinephrine or vasopressin. The hypertensive effect of norepinephrine (1.8 mg/kg/day intraperitoneal (i.p.)) or vasopressin (7.2 U/kg/day i.p.) was completely abolished by simultaneous administration of enalapril (6 mg/kg/day i.p.). The antihypertensive effect of enalapril was not reversed by simultaneous administration of subpressor doses of angiotensin II (36 and 100 μg/kg/day i.p.). However, the hypertensive effects of angiotensin II at pressor doses (600 and 900 μg/kg/day i. p.) in enalapril-infused rats were not different from those in vehicle-infused rats. These results indicate that the hypotensive effect of enalapril may in part depend on a reduced sensitivity of the vasculature to norepinephrine and vasopressin, independent of inhibition of angiotensin II formation.

Journal

Journal ID (publisher-id): NEF

Journal ID (nlm-ta): Nephron

Journal ID (doi): 10.1159/issn.1660-8151

Title: Nephron

Publisher: S. Karger AG

ISBN: 978-3-8055-5180-9

ISBN: 978-3-318-01967-4

ISSN (Print): 1660-8151

ISSN (Electronic): 2235-3186

Publication date Subscription-year: 1990

Publication date (Print): 1990

Publication date (Electronic): 16 December 2008

Volume: 55

Issue: Suppl 1

Pages: 81-84

Affiliations

^aSecond Department of Internal Medicine, Tohoku University School of Medicine, Sendai; ^bDepartment of Clinical Biology and Hormonal Regulation, Tohoku University School of Medicine, Sendai; ^cDepartment of Medicine, Hanamaki General Hospital, Hanamaki, Japan

Article

Publisher ID: 186042 Other ID: Nephron 1990;55:81–84

DOI: 10.1159/000186042

PubMed ID: 2345595

Copyright statement: © 1990 S. Karger AG, Basel

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Page count

Pages: 4

Product

Self URI (application/pdf): https://www.karger.com/Article/Pdf/186042

Self URI (text/html): https://www.karger.com/Article/FullText/186042

Self URI (journal page): https://www.karger.com/SubjectArea/Nephrology

Categories

Subject: Poster Session